Question · Q4 2021
Chris Neyor from JPMorgan asked for clarification on the Q4 discrepancy between EYSUVIS's 21% prescription growth and its lower reported sales, questioning the role of patient assistance or inventory dynamics. He also asked if the recent UnitedHealthcare win sufficiently addresses payer coverage headwinds and what further coverage can be expected in 2022.
Answer
Todd Bazemore, President and COO, clarified that both demand and ex-factory volume were up in Q4, but revenues were down due to a negative impact on gross-to-nets from the co-pay assistance program. Regarding coverage, he stated the UnitedHealthcare win puts them in a position of strength at 70% commercial coverage, with CVS Caremark being the next major target. For Medicare, he noted they are at 15% coverage and have submitted bids to major plans, expecting to learn more throughout 2022.